Related Experiment Video
Updated: Jun 11, 2026
Dioscin Mediated IgA Nephropathy Alleviation by Inhibiting B Cell Activation In Vivo and Decreasing Galactose-Deficient IgA1 Production In Vitro
Published on: October 13, 2023
Effect of Anti-IL-23 and Anti-IL-17 Therapy on Darier Disease: A Case Series
Maione Vincenzo1, Zanghi Silvia1, Catapano Cecilia1
1Dermatology Department, Spedali Civili, Università di Brescia, Brescia, Italy.
Abstract:
Darier disease is a rare ATP2A2-related genodermatosis for which therapeutic options remain limited, as acitretin is often constrained by toxicity and teratogenicity. In this retrospective real-world case series of eight patients, anti-IL-17 therapy showed a more consistent early signal of clinical benefit than anti-IL-23 therapy, with greater improvement in disease severity and patient-reported outcomes and no reported adverse events. Although limited by the small sample size and attrition over time, these findings support further prospective evaluation of biologic therapies in Darier disease.
Insights
Anti-interleukin-17 (IL-17) therapy demonstrated early clinical benefits for Darier disease patients, outperforming anti-interleukin-23 (IL-23) therapy with improved outcomes and no adverse events in a small case series.
Area of Science:
- Dermatology
- Immunology
- Genetics
Background:
- Darier disease is a rare genodermatosis linked to ATP2A2 gene mutations.
- Limited therapeutic options exist, with acitretin use restricted by toxicity and teratogenicity.
- Novel biologic therapies are needed for effective Darier disease management.
Purpose of the Study:
- To evaluate the real-world effectiveness of anti-IL-17 and anti-IL-23 therapies in Darier disease.
- To compare the clinical benefits and safety profiles of these biologic agents.
- To identify potential new treatment avenues for Darier disease.
Main Methods:
- Retrospective case series analysis of eight Darier disease patients.
- Assessment of clinical benefit signals for anti-IL-17 versus anti-IL-23 therapies.
- Evaluation of disease severity and patient-reported outcomes.
Main Results:
- Anti-IL-17 therapy showed a more consistent early signal of clinical benefit compared to anti-IL-23.
- Greater improvements in disease severity and patient-reported outcomes were observed with anti-IL-17.
- No adverse events were reported with anti-IL-17 therapy during the study period.
Conclusions:
- Findings suggest anti-IL-17 therapy may be a promising treatment for Darier disease.
- Further prospective studies are warranted to confirm the efficacy and safety of biologic therapies.
- Anti-IL-17 and anti-IL-23 represent potential therapeutic strategies for managing Darier disease.
